Alembic Pharmaceuticals Limited has officially announced receiving final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Dapagliflozin Tablets in 5 mg and 10 mg strengths. The company made this announcement through a regulatory filing under Regulation 30 to the stock exchanges.

Regulatory Approval and Market Position

The approved ANDA is therapeutically equivalent to the reference listed drug product Farxiga Tablets of AstraZeneca AB. Dapagliflozin tablet is a sodium-glucose cotransporter 2 (SGLT2) inhibitor with dual therapeutic indications for adults with type 2 diabetes mellitus.

Generic Drug Exclusivity Benefits

Alembic Pharmaceuticals was among the first ANDA applicants to submit a substantially complete application with paragraph IV certification for Dapagliflozin Tablets. This strategic positioning has earned the company eligibility for 180 days of shared generic drug exclusivity, providing a competitive advantage during the initial market launch period.

Market Opportunity and Commercial Impact

According to IQVIA data, Dapagliflozin tablets in 5 mg and 10 mg strengths represent an estimated market size of USD 10,487 million for the twelve months ending December 2025. This substantial market opportunity reinforces the commercial significance of the USFDA approval for Alembic Pharmaceuticals.

Regulatory Portfolio Expansion

With this latest approval, Alembic Pharmaceuticals has achieved a cumulative total of 235 ANDA approvals from the USFDA, comprising 217 final approvals and 18 tentative approvals. This milestone demonstrates the company's consistent regulatory success and strengthens its position in the US generic pharmaceutical market.

Therapeutic Applications

The approved Dapagliflozin tablets serve dual therapeutic purposes for adults with type 2 diabetes mellitus. The medication is indicated to reduce the risk of hospitalization for heart failure in patients with established cardiovascular disease or multiple cardiovascular risk factors, and as an adjunct to diet and exercise for improving glycemic control.

Alembic Pharmaceuticals Limited has officially confirmed the appointment of Mr. Chirayu Amin as Executive Chairman, effective April 1, 2026. The company has formally notified stock exchanges BSE and NSE about this leadership transition through regulatory filing under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Appointment Details and Regulatory Compliance

The appointment follows comprehensive shareholder approval obtained during the company's 15th Annual General Meeting held on August 5, 2025. The company has fulfilled all regulatory requirements and submitted the necessary documentation to both BSE and NSE.

Leadership Transition and Role Change

Mr. Chirayu Amin has relinquished his position as Chief Executive Officer upon completion of his former tenure as Chairman & CEO on March 31, 2026. This strategic transition maintains leadership continuity while restructuring executive responsibilities.

The company has confirmed that Mr. Amin is not debarred from holding the office of Director by virtue of any SEBI order or any other regulatory authority. All AGM proceedings were submitted to stock exchanges on August 5, 2025, ensuring complete transparency.

Professional Background and Company Impact

Mr. Amin brings substantial educational credentials to his role, holding a bachelor's degree in science from Maharaja Sayajirao University of Baroda and a master's degree in business administration from Seton Hall University, New Jersey, USA.

Under his leadership, management and guidance, the company has witnessed exceptional growth. He has played a pivotal role in steering the company towards sustained growth and innovation, with his continued association expected to be valuable for long-term success.

Social Initiatives and Family Connections

Beyond corporate responsibilities, Mr. Amin maintains active involvement in philanthropic initiatives as trustee with Bhailal Amin General Hospital, Uday Education Society, and Bal Utkarsh Society. Through these trusts, he has contributed significantly to initiatives improving access to quality healthcare, supporting educational institutions, and promoting social welfare.

The appointment maintains family involvement in leadership structure, as Mr. Chirayu Amin is the father of Mr. Pranav Amin and Mr. Shaunak Amin, who serve as Managing Directors of Alembic Pharmaceuticals. This relationship has been disclosed in accordance with corporate governance requirements.